Enanta Pharmaceuticals (ENTA) Times Interest Earned (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Times Interest Earned came in at -$1.54 in Q1 2026, up 89.23% YoY from -$0.81 in Q1 2025, and up 57.78% on a QoQ basis from -$3.65 in Q4 2025.
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) Times Interest Earned (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Times Interest Earned data on file, last reported at -$1.54 in Q1 2026.
- Quarterly Times Interest Earned rose 89.23% year-over-year to -$1.54 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.85 (down 200.54% YoY) and the FY2025 annual result came in at -$0.6, up 94.23% from the prior year.
- Times Interest Earned improved to -$1.54 in Q1 2026, from -$3.65 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of -$0.21 in Q2 2025 to a low of -$18.38 in Q2 2023.
- A 5-year average of -$5.3 and a median of -$2.22 in 2025 frame the typical range for Times Interest Earned.
- Annual changes were most pronounced in 2023 — Times Interest Earned slumped 6335.9% — and 2024, when it jumped 96.11%.
- Tracing ENTA's Times Interest Earned over 5 years: stood at -$1.7 in 2022, then slumped by 496.15% to -$10.14 in 2023, then increased by 22.8% to -$7.83 in 2024, then surged by 53.37% to -$3.65 in 2025, then surged by 57.78% to -$1.54 in 2026.
- The last three Times Interest Earned figures came in at -$1.54 (Q1 2026), -$3.65 (Q4 2025), and -$2.22 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 1.42 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -0.08 |
| 10 | Enanta Pharmaceuticals | 408.71 Mn | 219.21 Mn | - | -4.17 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4.17 |
| Mar 31, 2026 | -3.57 |
| Dec 31, 2025 | -3.65 |
| Sep 30, 2025 | -7.70 |
| Jun 30, 2025 | -11.68 |
| Mar 31, 2025 | -14.31 |
| Dec 31, 2024 | -12.00 |
| Sep 30, 2024 | -11.57 |
| Jun 30, 2024 | -10.27 |
| Mar 31, 2024 | -12.78 |
| Dec 31, 2023 | -10.14 |
| Sep 30, 2023 | -9.85 |
| Jun 30, 2023 | -18.38 |
| Dec 31, 2017 | 1,597.44 |
| Sep 30, 2017 | 6,032.78 |
| Jun 30, 2017 | -1,193.55 |
| Mar 31, 2017 | -1,188.25 |
| Dec 31, 2016 | -587.17 |
| Sep 30, 2016 | -281.73 |
| Jun 30, 2016 | -99.00 |